📰 Full Story
President Donald Trump on April 18 signed an executive order directing federal agencies to accelerate research and regulatory review of certain psychedelic drugs, including ibogaine, psilocybin and others, as potential treatments for severe mental illness and post-traumatic stress disorder.
The order instructs the Food and Drug Administration to issue national priority review vouchers for three psychedelics to shorten review times, clears a path for the first U.S. human trials of ibogaine and expands use of the Right to Try pathway for eligible patients.
The administration pledged about $50 million in federal‑state funding for psychedelic research and ordered coordination among HHS, the FDA, the Department of Justice and the VA. The signing in the Oval Office included HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, podcaster Joe Rogan and veterans advocates such as Marcus Luttrell.
Ibogaine remains a Schedule I substance in the U.S. and has known cardiac risks; researchers and regulators have warned safety concerns and limited evidence require careful clinical study before approval or rescheduling.








💬 Commentary